Does higher mean platelet volume reflect larger, more reactive platelets and cardiovascular risk?

Mean platelet volume (MPV) is a widely available clinical marker of average platelet size that provides critical insights into platelet biology and cardiovascular disease progression.

Mechanistic explanations

• Platelet Biogenesis: Inflammatory cytokines such as IL-3 and IL-6 increase megakaryocyte ploidy during platelet production, leading to the release of larger, younger, and denser platelets.
• Functional Hyperreactivity: These larger platelets contain a greater concentration of alpha and dense granules, synthesize higher levels of thromboxane A2, and feature increased surface expression of key activation and adhesion receptors, including glycoprotein IIb/IIIa and P-selectin. This leads to enhanced intracellular calcium mobilization.
• Pharmacological Modulation: Reflecting these active biological pathways, statin therapy has been shown to significantly modulate and reduce MPV in patients at risk for cardiovascular disease.

Clinical and prognostic evidence

• Coronary Artery Disease Outcomes: In patients with coronary artery disease (CAD) or acute coronary syndrome (ACS), every 1 fL increase in admission MPV is associated with an estimated 29% to 33% higher risk of long-term mortality.
• Myocardial Infarction: In patients experiencing acute myocardial infarction (AMI), elevated MPV is linked to a 1.6- to 2.6-fold increase in short- and long-term mortality, as well as a higher occurrence of the coronary no-reflow phenomenon.
• Vascular Mortality: Population-level data demonstrate that individuals in the highest quintile of MPV experience a 50% to 80% higher risk of ischemic heart disease and vascular mortality compared to those in the lowest quintile.

Bottom line

• Elevated mean platelet volume is a biologically robust indicator of larger, hyperreactive platelets driven by inflammatory signaling, serving as a powerful independent predictor of adverse thrombotic and inflammatory cardiovascular events.